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In patients with symptomatic incurable metastatic colorectal cancer (mCRC), the goal of resection of the primary lesion is 
to palliate cancer-related morbidity, including obstruction, bleeding, or perforation. In patients with asymptomatic primary 
tumors and incurable metastatic disease, however, the necessity of primary tumor resection is less clear. Although several 
retrospective analyses suggest survival benefit in patients who undergo resection of the primary tumor, applying this older 
evidence to modern patients is out of date for several reasons. Modern chemotherapy regimens incorporating the novel 
cytotoxic agents oxaliplatin and irinotecan, as well as the target agents bevacizumab and cetuximab, have improved median 
survival from less than 1 year with the only available single-agent 5-fluorouracil until the mid-1990s to over 2 years. In ad-
dition to significant prolongation of overall survival, combinations of novel chemotherapeutic and target agents have allowed 
improved local and distant tumor control, decreasing the likelihood of local tumor-related complications requiring surgi-
cal resection. Resection of an asymptomatic primary tumor risks surgical complications and may postpone the administra-
tion of chemotherapy that may offer both systemic and local control. In conclusion, the morbidity and the mortality of un-
necessary surgery or surgery that does not improve quality of life or survival in patients with mCRC of a limited life ex-
pectancy should be carefully evaluated. With the availability of effective combinations of chemotherapy and target agents, 
systemic therapy for the treatment of life-threatening metastases would be a preferable treatment strategy for unresectable 
asymptomatic patients with mCRC.
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metastatic CRC (mCRC) is an important oncologic issue.
Recent advancements in combination chemotherapy and target 
agents for CRC have increased the survival of incurable mCRC 
remarkably compared with that in the 1990s when 5-fluorouracil 
(5-FU) was the only available active agent [3]. Nonetheless, less 
than 10% of patients with mCRC are alive at 5 years, with most 
patients dying from their cancer [4]. In mCRC, a palliative surgi-
cal resection of the primary tumor can be performed to prevent 
tumor-related complications, such as obstruction, bleeding and 
perforation, and thus to minimize cancer-related morbidities. In 
selected patients, long-term survival can be expected when both 
the primary and all metastatic diseases are ressected. However, re-
section of the primary tumor in patients with mCRC is associated 
with 1-6% of surgical mortality and 20-30% of postoperative mor-
bidity [5-9]. Therefore, potential morbidities and adverse impacts 
on quality of life associated with treatment, as well as survival ben-
efit, should be considered seriously when treating patients with 
mCRC, for whom a limited life expectancy is predicted.
No standard treatment guidelines have yet been established for 
primary treatment of patients with asymptomatic primary tumors 
INTRODUCTION
According to the 2010 cancer statistics from the Ministry of Health 
and Welfare, Korea, colorectal cancer (CRC) in 2008 accounted 
for 12.7% (22,623 cases) of all cancers and was reported to be third 
leading primary type of cancer after stomach and thyroid cancer 
(second after stomach cancer in men, and fourth after thyroid, breast 
and stomach cancer in women) [1]. About 20-25% of patients with 
CRC are known to present with metastases at the time of initial 
diagnosis [2]. Therefore, appropriate management of patients with 
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and incurable metastatic disease. In these circumstances, two treat-
ment strategies can be considered. First, as in patients with symp-
tomatic primary tumors and incurable metastatic disease, resec-
tion of asymptomatic primary tumors can be performed to prevent 
later tumor-associated complications. Second, primary chemo-
therapy using novel agents can be tried without surgical resection. 
Here, evidence supproting palliative primary tumor resection in 
incurable mCRC was critically reviewed and compared with evi-
dence supporting chemotherapy using novel cytotoxic and target 
agents.
RETROSPECTIVE ANALYSES OF AND 
RESPONSE TO CHEMOTHERAPY
To date, no prospective randomized studies exist to guide standard 
treatment in patients with incurable mCRC. Considering treatment 
of these patients with a limited life expectancy, such issues as sur-
vival benefit of a treatment option, treatment-related complica-
tions (including morbidity and mortality), and their impact on 
quality of life should be weighed. The ultimate goal of treating un-
resectable mCRC should be palliative and be focused on prolon-
gation of survival and maintenance of quality of life.
In patients with symptomatic primary tumors and unresectable 
metastatic disease, palliative resection of the symptomatic primary 
tumor is often required because of cancer-related complications, 
such as obstruction, intractable bleeding, and perforation. Although 
surgical resection can palliate symptoms associated with primary 
lesions effectively, a serious consideration should be paid to surgi-
cal complications and mortality. As previously mentioned in the 
introduction, morbidity and mortality associated with palliative 
resection cannot be ignored [5-9]. Surgical problems associated 
with palliative resection of colorectal primary should be consid-
ered seriously, in particular, in patients with asymptomatic incur-
able mCRC. There is no level I evidence for selected treatment (pri-
mary colorectal resection or primary chemotherapy) of patients 
with asymptomatic unresectable mCRC. No prospective random-
ized trials concerning this issue exist. Although some non-random-
ized, retrospective reviews suggest a gain in survival from resec-
tion of the asymptomatic primary tumors [6, 9-11], this survival 
benefit was thought to reflect selection bias; that is, patients were 
not randomly selected at all, and patients selected for surgery tended 
to be those with lower tumor burden, higher performance status, 
and younger age. Therefore, comparing the survival of those pa-
tients with patients who had undergone primary chemotherapy 
seems to be of no value. Moreover, The most commonly used che-
motherapeutic agent in those retrospective studies was 5-FU, which 
could not prolong median survival by even a year, far less than the 
survival benefits offered from the combination regimens currently 
available. Recently, novel cytotoxic agents, such as oxaliplatin and 
irinotecan, and target agents, such as bevacizumab (monoclonal 
antibody for vascular endothelial growth factor) and cetuximab 
(monoclonal antibody for epidermal growth factor receptor), have 
been developed and are now widely being used for treatment of 
unresectable mCRC, whereby the median survival of less than a 
year achieved by using single 5-FU has been increased to over two 
years in recent years [3]. Table 1 summarizes the outcomes of sev-
eral major trials that define the standard of care using modern che-
motherapy in mCRC [12-16].
SELECTION OF TREATMENT IN PATENTS 
WITH ASYMPTOMATIC UNRESECTABLE 
MCRC
To date, medical evidence for the selection of treatment for asymp-
tomatic unresectable/incurable mCRC is still insufficient, and it 
would be important to consider the following several factors in 
the determination of a proper option:
Response of the primary colorectal tumor to chemotherapy
In mCRC, oncologic assessments of chemotherapy currently avail-
able are primarily focused on the presence or absence of response 
to metastatic lesions. If this is the case and primary chemotherapy 
without surgery of the primary tumor is planned in patients with 
unresectable asymptomatic mCRC, whether the primary tumor, 
as well as metastatic lesions, is responsive to chemotherapy or not 
must be considered. Chau et al. [17] analyzed a phase II study eval-
uating the effect of neoadjuvant chemotherapy on 77 patients with 
poor-risk rectal cancer. Patients received 12 weeks of capecitabine  Table 1. Novel chemotherapy regimens for colorectal cancer






   XELOX ± bevacizumab [12]
  899 38 21.3
FOLFOX-4 + cetuximab [13]   337 46 NA
CRYSTAL: FOLFIRI + cetuximab [14] 1198 47 24.9
BRiTE tumor registry [15]   642 48 31.8
GONO: FOLFOXIRI [16]   122 60 22.6
FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; XELOX, capecitabine and oxali-
platin; FOLFIRI, 5-fluorouracil, leucovorin, and irinitecan; GONO, Gruppo Onco-
logico Nord Ovest; FOLFOXIRI, FOLFOX, and irinotecan.

















Pelvic pain/tenesmus 45 32   71 66
Diarrhea/constipation 50 45   90 44
Rectal bleeding 27 27 100   7
Weight loss 14 13   93 21Journal of The Korean Society of
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and oxaliplatin (XELOX regimen) prior to neoadjuvant chemora-
diotherapy using capecitabine. Based on an assessment of evidence 
of rectal bleeding, pelvic pain, tenesmus, diarrhea, and constipa-
tion, the objective response rate after 12 weeks of neoadjuvant 
XELOX was 88%, and 86% of the patients with symptoms im-
proved. Specifically, pelvic pain/tenesmus was decreased in 71% 
of the patients, 90% had improvement in diarrhea/constipation, 
and 100% had reduced rectal bleeding (Table 2) [17]. These results 
suggest that the response of the primary tumor to chemotherapy 
is, at least, equivalent to that of metastatic lesions and that primary 
chemotherapy without surgery can be a preferred treatment strat-
egy in patients with asymptomatic unresectable mCRC.
The response rate of primary chemotherapy in mCRC using 5- 
FU/leucovorin used to be about 20%; however, combinations of 
infusional 5-FU/leucovorin with oxaliplatin (FOLFOX) or irino-
tecan (FOLFIRI) have yielded response rates of 50% [18, 19]. Fur-
thermore, the addition of a target agent, bevacizumab or cetux-
imab, to the above combinations has provided clinically meaning-
ful improvement in response rate and survival for these patents [13, 
14, 20, 21]. When target agents are used, toxicity associated with 
administration needs to be kept in mind. For example, bevacizumab 
has been associated with a 1% to 2% incidence of gastrointestinal 
perforation, and the risk of perforation at the site of the primary 
tumor is increased when the agent is administered in patients with 
unresectable mCRC with the primary tumor in situ [22]. When 
considering the administration of cetuximab, the KRAS mutation 
status of tumors should be examined because survival benefit is 
seen mainly in patients with wild type KRAS [13, 14].
Risk of complications in the primary tumor
When planning primary chemotherapy without surgery in patients 
with asymptomatic unresectable mCRC, the risk of primary tu-
mor-related complications (e.g., obstruction, bleeding and perfo-
ration), which require operative or nonoperative intervention, dur-
ing treatment can be considered as a second factor. In other words, 
when performing primary chemotherapy while leaving the primary 
tumor intact, the concern is whether the risk of developing primary 
tumor-related complications during chemotherapy would be sig-
nificantly higher as compared to when the primary tumor is sur-
gically resected. A clear conclusion about this issue can be attained 
from the evidence analyzed by Poultsides et al. [23]. They analyzed 
the frequency of interventions necessary to palliate the intact pri-
mary tumor in patients who present with synchronous, stage IV 
CRC and who receive up-front modern combined chemotherapy 
(FOLFOX, IFL, FOLFIRI/±bevacizumab) without prophylactic 
surgery. Of 233 patients, 207 (89%) never required surgical pallia-
tion of their primary tumor. Sixteen patients (7%) required emer-
gent surgery for primary tumor obstruction or perforation, and 
10 patients (4%) required nonoperative intervention, such as stent 
or radiotherapy (Fig. 1) [23]. Tebbutt et al. [24] also compared the 
incidence of major intestinal complications in patients who re-
ceived chemotherapy treatment with or without prior palliative re-
section of the primary tumor. Intestinal obstruction affected 13.4% 
of the patients in the unresected group and 13.2% of the patients 
in the resected group (P = 0.96). The incidences of peritonitis, fis-
tula formation, and intestinal hemorrhage in the unresected group 
were not significantly different from those in the resected group, 
either. Such evidence suggests that chemotherapy may be success-
fully used as an initial treatment for patients who have not under-
gone an initial resection of the primary tumor with no increased 
risk of most major intestinal complications compared with patients 
who have undergone an initial resection of the primary tumor. 
Moreover, palliative resection of an asymptomatic primary tumor 
may unnecessarily subject patients to surgery-related complica-
tions, and these potential surgical complications may postpone 
the administration of chemotherapy, which may offer better sur-
vival benefit. 
Recently, nonoperative interventions have widely used to treat 
obstruction or bleeding from primary colorectal tumors. A self-
expanding metallic stent (SEMS) by an endoscopic or an interven-
tional radiologic approach can restore bowel patency effectively in 
many patients with malignant colon or rectal obstruction. Camunez 
et al. [25] reported excellent results of SEMS in the treatment of 
malignant colorectal obstruction: stent placement was successful 
in 70 of the 80 patients and resolved bowel obstruction in 67 pa-
tients (96%). In addition, more than 90% of stents remained pat-
ent for 6 months or more following placement. Clinically signifi-
cant bleeding is present in about 10% of patients with mCRC [3], 
Total cohort 
(n = 233, 100%)
No primary tumor 
complication 













(n = 10, 4%)
Operative 
intervention 
(n = 16, 7%)
Primary tumor 
complication 
(n = 26, 11%)
No intervention 
(n = 152, 65%)
Curative 
resection 
(n = 47, 20%)
Preemptive 
resection 
(n = 8, 3%)
Fig. 1. Outcomes of unresected primary tumors in 233 patients with 
synchronous stage IV colorectal cancer who received modern combi-
nation chemotherapy. Curative resections, combined resections of 
colorectal tumor and metastatic disease, were elective. Preemptive re-
sections were performed in asymptomatic patients undergoing hepatic 
artery infusion pump placement. EBRT, external-beam radiation ther-
apy for rectal cancer palliation.Journal of The Korean Society of
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and although not commonly practiced in Korea, endoscopic laser 
therapy, cryotherapy, radiation therapy, and photodynamic ther-
apy may be effective in controlling bleeding [26, 27]. Pelvic or per-
ineal pain secondary to local invasion in patients with locally ad-
vanced rectal cancer can be alleviated effectively by radiotherapy.
Recent evidences support primary chemotherapy without pro-
phylactic resection of the primary tumor in patients with asymp-
tomatic mCRC does not increasing the risk of most tumor-asso-
ciated intestinal complications compared with patients who have 
undergone an initial resection of the primary tumor. Thus, this ap-
proach, chemotherapy without resection, can be used as the stan-
dard practice in patients with asymptomatic primary colorectal 
tumors and unresectable metastatic diseases.
Survival rate
Several retrospective analyses report survival benefit from resec-
tion of the primary tumor; the median survival ranged from 14 to 
23 months, which is more favorable than the 8.2 to 22 months in 
patients with chemotherapy as the first treatment [5, 6, 24, 26, 28, 
29]. Although Tebbutt et al. [24] described a median survival of 
8.2 months in the group initially treated with chemotherapy com-
pared with 14 months in the group initially treated with resection, 
a multivariate analysis revealed that performance status and the 
presence of peritoneal or omental metastases were significant fac-
tors affecting survival and that resection status of the primary tu-
mor was not significantly associated with survival. The study of 
Ruo et al. [6] also showed a survival benefit in the resection group 
(16 vs. 9 months), but resection status was not significantly asso-
ciated with survival from a univariate analysis. Another point to 
consider would be the chemotherapeutic agent administered. Most 
retrospective analyses reflect systemic chemotherapy using a sin-
gle agent, 5-FU, prior to the availability of oxaliplatin, irinotecan, 
bevacizumab, and cetuximab. As mentioned earlier, recent novel 
cytotoxic agents and target agents have increased survival to over 
two years in patients with unresectable mCRC. Considering these 
survival benefits obtained by administering modern chemothera-
peutic regimens, no further survival benefit can be obtained by 
resection of the primary tumor in patients with asymptomatic un-
resectable mCRC. In this sense, it is desirable to carry out initial 
primary chemotherapy using the novel cytotoxic and target agents 
in patients with asymptomatic unresectable mCRC. The National 
Comprehensive Cancer Network (NCCN) guideline, 2011 also rec-
ommends initial chemotherapy using various novel agents for the 
primary treatment for non-obstructive unresectable mCRC [30].
CONCLUSION
For patients with incurable mCRC, resection of the asymptomatic 
primary tumor provides little palliative benefit, can give rise to 
major morbidity and mortality, and may potentially postpone the 
administration of systemic chemotherapy of high response. In pa-
tients with unresectable mCRC, initial resection of the primary 
tumor should only be performed after careful consideration and 
should be reserved for patients who may develop primary tumor-
specific complications. With the availability of effective novel agents, 
systemic chemotherapy should be the preferred treatment strat-
egy for unresectable asymptomatic patients with mCRC.
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